NeuroRelease

**NeuroRelease** is a proprietary drug delivery platform developed by PixarBio Corporation for sustained release of non-opiate analgesics, primarily using poly(lactic-co-glycolic acid) (PLGA), an FDA-approved biodegradable polymer, combined with carbamazepine, an FDA-approved anticonvulsant with analgesic properties. It provides **morphine-strength pain relief** without addiction risk by selectively targeting sensory pain nerve fibers while sparing locomotion fibers, enabling patient mobility. Targeted for post-operative, acute, chronic, and battlefield pain via formats like 14-day implants, 7-day treatments, and "sprinkle-on" sterile powders; pursued FDA approval via 505(b)(2) pathway leveraging established safety data, with first approval anticipated around 2018-2019.[2][5][10]

Brand names

NeuroRelease